Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of quercetin in adult patients with autism spectrum disorder
IRCT20241214064050N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of quercetin in Autism Spectrum Disorder (ASD), sponsored by Tehran University of Medical Sciences. Started Jan 2025; status: completed.
02
Drugs
quercetin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20241214064050N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241214064050N1.